drugset / Trial / NCT04972175
Safety and Efficacy of BC LisPram
RandomizedCrossoverOpen-labelTreatment
Summary
This pilot study is a 50-hour randomized, open-label, crossover study in an inpatient setting assessing the safety, pharmacodynamics, pharmacokinetics, and closed-loop efficacy of i) BC LisPram delivery and ii) rapid insulin delivery.
Timeline
- Start
- 2021-07-28
- Primary completion
- 2022-06
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC LisPram | Unknown | — | Subcutaneous |
| Comparator | Insulin Lispro | Protein / enzyme biologic | — | Subcutaneous |